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To search for autoantigens in psoriatic plaques, we screened cDNA libraries of plaque epidermis with psoriatic
serum samples. This approach has been highly successful in identifying tumor antigens, but has not been widely
applied to autoimmune disease. We identiﬁed 11 autoantigens including three with prominent reactivity and
plausible disease relevance. These are keratin 13 (K13), heterogeneous nuclear ribonucleoprotein-A1 (hnRNP-A1),
and a previously uncharacterized protein, FLJ00294. Serum antibody screening for these demonstrated reactivity in
40%, 38%, and 27% of psoriasis patients, respectively. Most positive samples reacted with all three, and we found
that this was due to cross-reactivity among them. Enzyme-linked immunospot assay (ELISPOT) analysis of
psoriatic peripheral blood T cells conﬁrmed that these autoantigens are also recognized by T cells. This
demonstrates that this is a feasible method to identify autoantigens in an autoimmune target tissue, and suggests
that these antigens warrant further study in psoriasis. Furthermore, but peripheral blood of normal controls reacted
to these autoantigens with essentially the same frequencies as patients, suggesting that psoriatics may have not
only an immune system which is capable of reacting to certain autoantigens, but also to a skin immunoregulatory
alteration which allows this normal reactivity to develop into abnormal inﬂammation.
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Current evidence suggests that a limited number of self-
antigens are normally recognized by the immune system
(Lacroix-Desmazes et al, 1998; Plotz, 2003), and that loss of
proper regulation of reactivity to these antigens contributes
to autoimmune disease (Bach et al, 1998; von Herrath and
Harrison, 2003). Although numerous autoantigens have
been described for certain organ-specific T-cell-mediated
autoimmune diseases such as multiple sclerosis and
diabetes (Mocci et al, 2000), many other autoimmune
diseases have few or no associated autoantigens de-
scribed. Furthermore, the mechanisms by which the
autoreactive T cells lead to disease are very difficult to
study because in the most widely studied diseases, tissue is
not easily accessible. It would therefore be of considerable
value to have a method capable of easily identifying
autoantigens recognized by T cells, and to define a set of
autoantigens in a common disease with easily accessible
tissue. In this report, we present progress toward these
goals. In order to identify autoantigens expressed in a target
organ, we use an approach that has been very successful in
the identification of antigens recognized by T cells in tumor
immunity. The studies are done in psoriasis, which is an
ideal model disease because it is common and tissue is
readily accessible.
Identification of antigens recognized by T cells in human
disease states has proved very difficult in the past, requiring
laborious methods such as isolating reactive T-cell clones
and eluting peptides from major histocompatibility complex
molecules. A new approach in the field of tumor immunity
has led to the identification of an enormous variety of T-cell
tumor antigens over the past several years. This approach
is termed SEREX3, for SErological identification of Re-
combinant EXpressed antigens, and is based on the
presence of both T- and B-cell reactivities to an antigen
mediated through a common set of helper T cells (Tureci
et al, 1997, 1999; Old and Chen, 1998). For these antigens,
the parallel B-cell response may have no significant role in
disease, but the existence of these antibodies can serve as
a marker for a corresponding set of T cells that react to the
same antigen. Since tumor immunity can be regarded as
one form of T-cell-mediated autoimmunity, and since there
is good experimental evidence for parallel B- and T-cell
responses in autoimmune diseases, we reasoned (as have
others; Krebs et al, 2003) that this approach could be used
to identify autoantigens in a T-cell-mediated autoimmune
disease. Our results demonstrate that this is a productive
approach. Screening proteins in expression libraries of
psoriatic plaque epidermis identified a limited subset (11
proteins) with high levels of autoreactive antibodies,
supporting the idea that the number of proteins capable
of serving as autoantigens is quite limited. Three of these
have especially high-level reactivity and plausible relevance
in psoriasis and psoriatic arthritis. We also verify using
ELISPOT analysis that T cells respond to these proteins at
levels that are similar to responses seen to established
autoantigens in other diseases.
Abbreviations: hnRNP-A1, heterogeneous nuclear ribonucleo-
protein-A1; K13, keratin 13; SEREX, SErological identification of
Recombinant EXpressed antigens
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Results
Library screening Libraries were screened using a com-
bined mixture of five psoriatic serum samples. Positive
plaques were purified by repeat rounds of plating, screen-
ing, and recovery of positive phage. Inserts were amplified
by PCR and sequenced, and each positive phage was then
tested for reactivity with up to 19 separate psoriatic serum
samples in a mixed plaque assay (see Table 1). Three
libraries were screened: two created from psoriatic plaque
epidermis and a commercially available cultured neonatal
foreskin keratinocyte library. Approximately 2  106 plaques
were screened from each library using the psoriatic serum
samples. This represents screening of approximately one
fifth of the total complexity of the libraries since complete
immunoscreening requires testing approximately ten times
the number of independent clones in the library. Based on
the library screening results, three antigens were selected
for further study using a larger number of psoriatic serum
samples and normal control samples.
Antibody responses against antigens Table 2 presents
the results of mixed plaque assays for 48 psoriatic subjects
and 28 normal controls. This assay gives a semiquantitative
measure of the antibodies to each protein in each serum
sample, which we have graded on a scale of þ to
þ þ þ þ (Fig 1 shows examples of the appearance of this
type of blot, with 1A graded as þ þ þ þ and 1B–D graded
as þ ). As shown in columns 1–3 of Table 2, 40% of
psoriatics have autoantibodies that react to K13, 38% to
hnRNP-A1, and 27% to FLJ00294. A prominent feature of
this data set is that subjects reacting strongly to one antigen
generally react to all three antigens. This interesting finding
can be explained by either of two possibilities: (1) some
people happen to have autoreactive antibodies to all three
of these proteins, or (2) the antibodies to these proteins
cross-react. An experimental artifact appears unlikely
because western blot results using purified recombinant
K13 and hnRNP-A1 confirm the specificity of all strongly
reactive serum samples, with rare reactivity in samples
negative in the mixed plaque assay (columns 4 and 5 of
Table 2). Very similar data was found for normal controls. Of
the 28 normal controls tested, 39% react to K13, 32% to
hnRNP-A1, and 29% to FLJ00294. The finding that strongly
reactive serum samples react to all three antigens was also
seen for normal controls. Western blot results again
confirmed the band specificity of strongly reactive serum
samples.
The mixed plaque assay was chosen to test for
autoantibodies because antigens generally fold well as b-
galactosidase fusion proteins and are minimally denatured
in the blotting process, and because no additional
subcloning is required. It also has a proved track record in
SEREX studies (Sahin et al, 1995; Robinson et al, 2000).
This was found to be considerably more sensitive than the
western blot assay for these proteins, with easily discern-
able dark spots on the phage blots but weak bands on the
western blots. This suggests that these epitopes are
conformation dependent and that sensitivity is lost in the
denaturation of SDS-PAGE. Consistent with this, all highly
reactive serum samples in the mixed plaque assay were
also positive in the western blot, whereas many of the
weakly positive serum samples in the mixed plaque assay
were not positive in the western blot. Also, several subjects
are positive in the western blot but not in the mixed plaque
assay (e.g., P27 in Table 2), which likely represents the
unmasking of irrelevant epitopes by SDS-PAGE and
suggests that the western blot also has lower specificity
compared with the mixed plaque assay. We also tried
testing humoral responses in an ELISA format using the
purified recombinant proteins (data not shown). This was
complicated by problems with trace contaminating E. coli
proteins not visible with Coomassie staining but which
sometimes produced prominent bands on western blot
analysis.
T-cell responses against antigens Figure 2 shows the
results of ELISPOT analysis. PBMC were available from 25
Table I. Insert sequencing and initial mixed plaque assay results for reactive phage
Phage insert sequence Accession number Psoriatic serum
Keratin 13 (transcript variant 1) NM_153490 6/19
Heterogeneous nuclear ribonucleoprotein-A1 NM_002136 6/19
Putative protein FLJ00294 AK122583 6/19
Bullous pemphigoid antigen 1 (BPAG1) NM_001723 3/19
Adenocarcinoma antigen ART1 AF197954 2/19
Chromosome 9 sequence AL354928 1/15
Putative protein FLJ10335 NM_018062 1/15
LIM protein (similar to rat protein kinase C-binding enigma) BC008741 1/14
Hepatocellular carcinoma-associated antigen 59 AF218421 1/14
Quinone oxidoreductase (NQO2) J02888 1/14
Chromosome 14 sequence NM_138288 1/14
Three cDNA expression libraries in lambda phage were created from psoriatic plaque epidermis and screened with a mixture of five psoriatic serum
samples. Reactive phage were plaque purified and inserts were sequenced (columns 1 and 2). The phage were then tested for reactivity with 14–19
individual psoriatic serum samples (column 3, reactive serum samples per total).
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Table II. Analysis of antibody responses against autoantigens for psoriatic and normal subjects
Sample K13 MPA hnRNP-A1 MPA FLJ00294 MPA K13 WB hnRNP-A1 WB
P1 þ þ þ þ þ þ þ þ þ þ
P6 þ
P9 þ þ þ
P10 þ þ þ þ þ þ þ
P11 þ þ þ
P12 þ þ þ þ
P15 þ þ þ
P16 þ þ þ þ þ þ þ
P17 þ þ
P18 þ þ þ þ þ þ þ þ þ þ þ þ
P21 þ þ þ þ þ þ þ þ þ þ þ þ
P22 þ þ
P24 þ þ þ
P26 þ
P27 þ þ þ
P30 þ þ þ
P31 þ þ
P39 þ þ þ þ þ þ þ þ þ þ þ þ þ þ
P40 þ þ þ þ
P43 þ þ þ þ þ
P44 þ þ þ
P46 þ þ þ
26 other
psoriatics
    
N1 þ þ þ þ
N2 þ
N4 þ
N6 þ þ þ þ þ
N9 þ
N12 þ
N15 þ þ þ þ þ þ þ þ
N16 þ þ þ þ þ þ þ þ þ þ þ
N21 þ
N22 þ þ þ
N23 þ þ þ þ þ þ þ þ þ þ þ þ




    
Serum samples from 48 psoriatic subjects and 28 normal controls were tested for autoantibodies to K13, hnRNP-A1, and FLJ00294 in the mixed plaque
assay (MPA). The same samples were also used in a western blot (WB) assay using purified recombinant K13 and hnRNP-A1. A blank cell indicates a
negative result. Subjects with all negative results are grouped together. K13, keratin 13; hnRNP-A1, heterogeneous nuclear ribonucleoprotein-A1.
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of the normal subjects and 16 of the psoriatic subjects.
These data have been separated from the data in Table 2
and are presented in graphical format for clarity and
comparison with other similar results. The first four columns
show the numbers of T cells reactive to K13 and hnRNP-A1
in each PBMC sample. The positive control recall antigen,
tetanus toxoid, gave very strong responses in most subjects
(columns 5 and 6), whereas most subjects had very few
spontaneously reactive cells (columns 7 and 8). The
FLJ00294 protein proved difficult to obtain in sufficient
quantity and purity for the ELISPOT assays and has not yet
been tested. Comparison of T-cell reactivity of each subject
with antibody reactivity did not yield any significant
correlation (data not shown).
Cross-reactivity among antigens Figure 1 shows results
of experiments that demonstrate cross-reactivity of the
antibodies among all three antigens. Figure 1A shows the
strong serum reactivity of subject P39 to K13 in a mixture
of K13 and negative control plaques. Antibodies from this
subject’s serum were bound to large plaque lifts of K13-
expressing phage, eluted, and used to probe K13, hnRNP-
A1, and FLJ00294 mixed plaque blots (Figs 1B–D). Assays
using antibodies eluted from hnRNP-A1- and FLJ00294-
expressing phage (not shown) produced weak but clear
reactivity on mixed plaque lifts of all three antigens that was
very similar to those shown. Assays using antibodies eluted
from non-recombinant phage showed no specific reactivity,
as expected (not shown). We also tried reacting the eluted
antibodies to western blot strips containing the three
recombinant proteins, but found that specific bands could
not be reliably discerned, which we believe is due to the
loss of sensitivity of the western blot relative to the mixed
plaque assay as was discussed above.
Discussion
Current evidence suggests that a limited number of self-
antigens are normally recognized by the immune system
(Lacroix-Desmazes et al, 1998; Plotz, 2003). This repertoire
of autoreactivity varies somewhat among individuals, but
overall is highly conserved, even across species, and
responses to these antigens remain stable throughout an
individual’s life. The total number of these autoantigens is
estimated to be in the low hundreds of proteins (Plotz,
2003). Responses to some autoantigens are reasonably
specific for disease, but in other cases reactivity is not
specific and in these cases, loss of proper regulation of
normal autoimmune reactivities along with elements of an
altered inflammatory response in target organs are postu-
lated to lead to autoimmune disease. The details of this,
however, remain elusive, especially for the autoimmune
diseases mediated predominantly by T cells (Bach et al,
1998; von Herrath and Harrison, 2003).
Our results demonstrate that the SEREX approach is
useful in the study of organ-specific T-cell-mediated
autoimmune disease by defining candidate autoantigens.
Primary screening revealed a limited number of antigens
Figure 1
Antibody cross-reactivity among antigens. (A) A mixed plaque assay
using pre-cleared serum sample P39 tested with an approximately 1:1
mixture of keratin 13 (K13) recombinant plaques and non-recombinant
control plaques. This serum sample was then adsorbed to a sheet of
confluent K13 plaques and bound antibodies were eluted and used to
probe mixtures of (B) K13, (C) heterogeneous nuclear ribonucleopro-
tein-A1, (D) FLJ00294 plaques with non-recombinant plaques. Each
assay is internally controlled with the intermixed non-recombinant
plaques, which appear fainter and less distinct than the antigen-
expressing plaques.
Figure2
ELISPOT testing of keratin 13 (K13) and heterogeneous nuclear
ribonucleoprotein-A1 (hnRNP-A1). Peripheral blood mononuclear
cells (PBMC) from psoriatic or normal subjects were incubated with
PAGE-purified recombinant antigen and spots formed by activated IFN-g
secreting cells were counted. Each symbol on the graph represents one
subject.
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(11) after screening approximately one-fifth of the total
library complexity, and a large fraction of subjects tested (up
to 40%) react to these. This supports the concept that there
is a very limited subset of proteins in a tissue that are
capable of serving as autoantigens, and that this subset is
similar among individuals (Lernmark, 2001; Plotz, 2003). We
estimate that in future work, full screening of the libraries
should be capable of identifying a relatively complete
repertoire of autoantibodies to components of psoriatic
plaque epidermis. One initial concern was interference by
autoantibodies to common proteins, such as anti-actin
autoantibodies or antibodies to heat shock proteins.
Another concern was the possibility that autoantibody
responses could be regulated to levels that are low
compared with tumor antigens or exogenous antigens. We
chose a 1:500 serum dilution for library screening as is
commonly done for tumor antigen SEREX, and found that a
subset of antigens with easily discernable reactivity could in
fact be identified.
Three antigens identified in the primary screening appear
promising based on high-level reactivity and plausible
disease relevance. K13 is an interesting antigen in several
respects. First, it has significant homology with K17, which
was previously identified as candidate autoantigen based
on the presence of both antibodies and T cells that cross-
react with a streptococcus M protein (Gudmundsdottir et al,
1999). Second, K13 is not present in adult skin normally, but
is present in fetal skin (van Muijen et al, 1987), and is
upregulated in regenerating epidermis (Kallioinen et al,
1995). This could potentially provide an explanation for the
Koebner phenomenon, in which lesions of psoriasis develop
in skin that has been traumatized. Third, K13 is present in
large amounts in non-keratinizing squamous epithelium
such as the tongue, esophagus, and cervix, and could
therefore be related to geographic tongue, which is thought
to be a localized psoriasis variant. Similarly, K13 is present
in genital and perianal epidermis (van Muijen et al, 1986;
Stoler et al, 1988) that are affected areas in the so-called
inverse psoriasis. Finally, expression of K13 is regulated by
retinoids (van Rossum et al, 2000a, b), and although this has
not been studied in the context of psoriasis, it could
potentially be related to the efficacy of some retinoids in the
treatment of psoriasis.
Heterogeneous nuclear ribonucleoprotein A1 (hnRNP-
A1) also has several interesting features as a candidate
autoantigen in psoriasis. It is a component of the spliceo-
some composed of three domains: two RNA-binding
domains and a carboxy terminal domain that is glycine-
rich and homologous to basic keratins. Although most anti-
RNP antibodies in connective tissue diseases bind to the
RNP-binding domains, there is a subset of rheumatoid
arthritis patients with antibodies to the keratin-homology
domain of hnRNP-A1 (Astaldi-Ricotti et al, 1989). This
subset of patients was further found to have anti-keratin
antibodies that cross-react with hnRNP-A1 and could be
removed by adsorption to purified hnRNP-A1 (Montecucco
et al, 1990). Our experiments were not designed to detect a
correlation between hnRNP-A1 reactivity and psoriatic
arthritis, but the possibility of such a relationship is
intriguing. Another previously demonstrated cross-reactivity
of hnRNP-A1 is HTLV-1 tax protein (Levin et al, 2002). No
association between psoriasis and HTLV-1 infection is
known, but infection with a related retrovirus producing
a protein similar to tax is an intriguing possibility in the
pathogenesis of psoraisis. These experiments were in fact
initially developed to account for the possibility of viral
antigens as well as autoantigens. The method only requires
that the antigen be expressed as mRNA in the target tissue,
not that it necessarily be a self-antigen.
The FLJ00294 insert nucleotide sequence matches
exactly to chromosome 8p11 sequence and the GENBANK
entry for the putative protein FLJ00294. NCBI BLAST
searching revealed that this protein is homologous to rat
and rabbit Rab interacting proteins, and also revealed a
match with K17. The significance of the homology with K17
remains to be verified since the corresponding peptides
have two amino acid mismatches: EGEDALVTQY for
FLJ00294 and EGEDAHLTQY for K17. Although both RNP
and FLJ00294 show some sequence homology to keratins
in general, it is important to note that analysis of the
antigenic insert of each clone does not indicate a single
region of homology common to K13, hnRNP-A1, and
FLJ00294. As a result, it can be concluded that the
antibody cross-reactivity is likely to involve secondary
structure (which is supported by the higher sensitivity of
the mixed plaque assay relative to western blotting), and
that some amount of epitope spreading may be involved.
Screening of K13, hnRNP-A1, and FLJ00294 with larger
numbers of serum samples (Table 2) demonstrates that high
percentages (up to 40%) of subjects react to these, and that
subjects with high-level antibodies appear to have cross-
reactive antibodies. This cross-reactivity was then con-
firmed directly by demonstrating that antibodies eluted from
K13 blots react with hnRNP-A1 and FLJ00294 (Fig 1). These
findings are strikingly similar to previous studies of auto-
antigens identified in autoimmune thyroid disease. Testing
of large numbers of subjects for antibodies to thyroglobulin
and thyroid peroxidase showed that most subjects with
high-level autoantibodies to one antigen have autoantibo-
dies to the other (Pedersen et al, 2003), and direct cross-
reactivity has been shown for thyroglobulin and thyroid
peroxidase using antibody elution experiments similar to
those performed here (Ruf et al, 1992). Also of potential
relevance is the finding that autoreactivity to these thyroid
antigens is an inherited trait. If such inheritance also proves
to be the case with these candidate autoantigens in
psoriasis, it could be related at least in part to the genetic
predisposition in psoriasis.
As is seen with many other autoantigens that have been
studied in T-cell-mediated autoimmune diseases, these
candidate autoantigens have similar antibody reactivity in
both patients and controls. It will therefore require more
detailed experiments to demonstrate the exact role of these
candidate autoantigens in psoriasis. One approach that
appears promising is to identify a more complete set of
autoantibodies with additional screening. In the case of
diabetes, where numerous autoantigens have been identi-
fied previously, it has been found that autoantibodies are
not disease specific when tested individually, but the
simultaneous presence of multiple antibodies has high
specificity for disease (reviewed in Leslie et al, 1999, see
also Maclaren et al, 1999). A more complete set of
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autoantigens in psoriasis might also demonstrate relation-
ships to disease prediction and classification as seen in
other diseases (Leslie et al, 2001).
One technical consideration in this application of SEREX
is the method used after initial screening to test larger
groups of serum samples. We found that the mixed plaque
assay, although requiring tedious serum pre-clearing, is
highly robust and very sensitive because it minimizes
antigen denaturation. Alternatives include an ELISA or
western blot using purified protein, and we tried each of
these. The ELISA is commonly used in tumor antigen
SEREX because it is quantitative and convenient. But we
found the ELISA unsatisfactory for measurement of these
autoantibodies due to trace E. coli contaminants in the
purified proteins. Western blotting avoids this problem by
verifying reactivity to a specific band, but we find that the
denaturation of SDS-PAGE decreases sensitivity for these
autoantibodies to an unacceptable degree. The conforma-
tion dependence and relatively low antibody concentrations
we find here suggest that, as has been found for most
antibody studies in diabetes and multiple sclerosis, radio-
immunoassay may be the best approach for screening large
numbers of samples in the future (Kawasaki and Eisenbarth,
2000). These issues may also place constraints on possible
alternative systems for probing autoantibody repertoires
(Hueber et al, 2002; Robinson et al, 2002).
Finally, our ELISPOT results confirm that these autoanti-
gens can also be recognized by peripheral blood T cells.
This is an important validation of the approach of using
antibodies as surrogate markers to screen for autoantigens
in T-cell-mediated autoimmune disease. Both the frequency
of positive responses and the magnitude of responses are
comparable with previous work with autoantigens in multi-
ple sclerosis (McCutcheon et al, 1997; Pelfrey et al, 2000;
Hellings et al, 2001) and diabetes (Alleva et al, 2001). We
had hoped for a correlation between antibody levels and
T-cell responses for each subject, but none was found. The
lack of such a correlation, however, has also been seen in
diabetes (Hummel et al, 1996; Narendran et al, 2003), as has
an inverse correlation in one instance (Harrison et al, 1993).
Studies of autoreactive T cells in other autoimmune
diseases have generally shown similar reactivity of periph-
eral blood T cells between patients and normal controls.
This is taken as evidence that it is insufficient to simply
recognize a self-antigen, and that a dysregulated inflam-
matory response within the target organ is critical for the
development of autoimmune disease (von Herrath and
Harrison, 2003). Our studies also demonstrate similar
peripheral blood reactivity among psoriatics and normal
controls, and therefore suggest that this concept applies
to psoriasis as well. Studies of cerebral spinal fluid (CSF)
T cells in multiple sclerosis (Chou et al, 1992; Zhang
et al, 1994) and lesional T cells in animal models of auto-
immune disease do show disease specificity in response
to autoantigens. We therefore anticipate that in future work,
the accessibility of lesional tissue in psoriasis will allow
studies of target organ damage that are currently not
possible in other human diseases. Other studies that may
prove useful in future work are peptide mapping to identify
immunodominant peptides of higher specificity than whole
proteins (Kerlero de Rosbo et al, 1997; Pelfrey et al, 2000;
Alleva et al, 2001; Tejada-Simon et al, 2001), and the use of
anti-CD28 blocking antibody to show a difference in the
activation state of antigen-specific T cells in patients relative
to controls (Lovett-Racke et al, 1998; Viglietta et al, 2002).
In summary, we have utilized an expression cloning
approach to identify novel autoantigens from libraries of
psoriatic plaque epidermis. This approach is based on the
SEREX method widely used to identify tumor antigens, and
appears to be a very practical alternative to other methods
of identifying antigens for T cells in autoimmune disease.
Three autoantigens that we have identified have plausible
relevance in psoriasis as well as patterns of antibody and
T-cell reactivity very similar to those seen in other
autoimmune diseases. Further study of these autoantigens
should provide significant additional insight into the
pathophysiology of psoriasis, and study of psoriasis may
in turn yield insights into other autoimmune diseases
through experiments that are practical only in this common
skin disease.
Materials and Methods
Patients All blood and biopsy samples were obtained following
informed consent according to an IRB-approved study protocol.
Psoriasis patients were eligible if they had active plaque-type
psoriasis regardless of severity. No patients received systemic or
ultraviolet light treatment for more than 1 mo prior to obtaining a
blood sample for antibody testing. Shave biopsies for library
production were obtained from untreated plaques. No patients had
an active or previous concominant diagnosis of bullous pemphioid.
cDNA library construction A cDNA library of cultured neonatal
foreskin keratinocytes in the lambda gt11 vector was purchased
from BD Biosciences Clontech, Palo Alto, California. Other libraries
were constructed in our laboratory as follows. Shave biopsies of
psoriatic plaque epidermis (approximately 1.5 cm2) were obtained
and total RNA was isolated using Trizol (Invitrogen, Carlsbad,
California). Full-length cDNA was created and amplified using 10–13
cycles of PCR as described previously (Lukyanov et al, 1997). To
improve stability and expression of the clones, cDNA was digested
with RsaI to obtain shorter cDNA fragments (average of 500 bp).
This was followed by ligation of EcoRI adapters, ligation into
lambda ZAP II arms (Stratagene, La Jolla, CA), packaging,
and library expansion using standard procedures. Libraries had
between 0.8 and 1.2  106 independent clones with 70%–80%
recombinants. The presence of b-actin-expressing clones was
verified by using a monoclonal antibody (Zymed, South San
Francisco, California) for immunoscreening.
cDNA library screening Libraries were screened using standard
immunoscreening protocols. In brief, isopropyl-beta-D-thiogalac-
topyranoside phosphate/nitro-blue tetrazolium-induced (Sigma,
Sigma-Aldrich, St. Louis, Missouri) plaque lifts on nitrocellulose
membrane (Stratagene) were blocked using 5% non-fat dried milk
(NFDM) in Tris-buffered saline with 0.05% Tween 20 (TBST),
washed with TBST, then incubated with serum samples diluted in
TBST overnight at 41C. Serum from five psoriasis patients was pre-
cleared extensively using plaque lifts of non-recombinant phage
and combined at 1:500 dilution each. The secondary antibody was
goat anti-human IgG conjugated to alkaline phosphatase (South-
ern Biotechnology #2040, 1:2000 dilution in TBST) and membranes
were developed using 5-bromo-4chloro-3indoxyl solution (Spec-
trum, New Brunswick, New Jersey). Positive spots were marked
and the corresponding phage plaques were recovered for repeat
rounds of plaque purification. Inserts of plaque purified phage were
sequenced by using PCR to create insert amplicons with T3 and
T7 primers for inserts in lambda ZAP II or lacZ-specific flanking
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primers for lambda gt11 (New England Biolabs, Beverly, Massa-
chusetts).
Mixed plaque assay Recombinant and control phage were mixed
1:1, plated at low density, blotted and screened as for the library
screening. After development, if dark and light plaques could not
be clearly differentiated a negative result was assigned. Positive
results were scored visually by two blinded investigators based on
the difference in intensity between dark and light plaques using a
scale of þ (weak), þ þ , þ þ þ , or þ þ þ þ (very strong). As
examples, Fig 1A would be graded as þ þ þ þ , and Figs 1B–D
would be graded as þ .
Recombinant proteins Antigenic inserts from the libraries were
partial length fragments ranging from 200 to 1200 bp. The
antigenic hnRNP A1 fragment (bases 447–950 of the 962 base
cDNA) covered almost the entire C-terminal keratin-homology
domain and a small portion (84 bp) of the RBD2 domain, and was
large enough for expression in Escherichia coli. The keratin 13
(K13) fragment (bases 1113–1376 of the 1376 bp cDNA) was too
small for expression so the full-length sequence was amplified
from psoriatic plaque RNA by RT-PCR and verified by direct
sequencing. The FLJ00294 phage insert (bases 607–1385 of the
partial length mRNA sequence available in accession AK122583)
was large enough for expression in E. coli. All inserts were
subcloned into the pQE-32 vector (Qiagen, Valencia, California) to
attach an N-terminal 6  histidine tag, and purified over Ni-NTA
(Qiagen) using the manufacturer’s protocols. Purified proteins were
checked for purity using SDS-PAGE and Coomassie staining. In all
cases, the major band was present at the correct molecular
weight, but additional lower molecular weight bands were also
present. These proved either degradation or pre-mature truncation
products when tested by western blot staining with anti-RGS-his
tag antibody (Qiagen).
Western blot Recombinant proteins were separated using SDS-
PAGE, blotted onto polyvinylidene difluride membranes, blocked
with 5% NFDM in TBST, washed, and cut into strips. Strips were
incubated with serum samples diluted 1:50 in TBST with 1% NFDM
for 2 h at room temperature. Strips were developed as above using
secondary goat anti-human IgG-AP antibody incubation for 1 h and
BCIP/NBT solution. Developed membranes were then assessed
visually by two blinded investigators for the intensity of bands at
the correct molecular weight. Semiquantitative grading of results
for the western blot was performed as for the mixed plaque assay
(þ to þ þ þ þ ).
ELISPOT PVDF ELISPOT plates (Millipore, Billerica, Massachu-
setts) were coated with anti-IFN-g antibody (BD BioSciences
Pharmigen, Palo Alto, California, clone NIB42) and blocked with
2% bovine serum albumin in TBST. Peripheral blood mononuclear
cells (PBMC) were purified by centrifugation through Ficoll–
Hypaque, washed, and resuspended in RPMI-1640 with 10%
human serum AB and penicillin/streptomycin/glutamine supple-
mentation. Purified recombinant antigens were added to 106
PBMC in 400 mL medium at 1 mg per mL for a 24 h pre-incubation
period in round-bottom polypropylene tubes for antigen presenta-
tion. Tetanus toxoid was purchased from the Massachusetts
Biologic Laboratories (Jamaica Plain, Massachusetts) and used
at 1 mg per mL. PBMC were then resuspended and transferred to
the plates at 2.5x105 PBMC/well in quadruplicate. After a 24 h
period for IFN-g secretion, plates were developed using a
biotinylated second anti-IFN-g antibody (BD Pharmingen, clone
4S.B3), streptavidin-alkaline phosphatase (BD Pharmingen), and
BCIP/NBT solution according to standard protocols. Spots were
counted manually by two blinded investigators, averaged, and then
averaged over the four replicate wells to give the number of spots
per 2.5  105 PBMC.
Antigen cross-reactivity experiments Three aliquots of serum
from a psoriatic subject with high-level antibody reactivity (P39)
were diluted 1:25 with TBST and pre-cleared extensively using
plaque lifts of non-recombinant phage. The serum aliquots were
then incubated with plaque lifts of high-density K13-, hnRNP-A1-
expressing plaques, or non-recombinant plaques. These plaque
lifts were then washed with TBST and incubated for 5 min in
stripping buffer (0.1 M glycine, 0.15 M NaCl, pH 2.75), which was
collected and immediately neutralized. The resulting antibody-
containing solutions were then incubated with mixed plaque lifts as
in the other mixed plaque assays.
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